Skip to main content
Toggle navigation
FR
EN
Drupal
Main navigation EN
About Crossject
Who we are
Governance
R&D
Our technology
ZENEO®: needle-free technology
Products under development
Our supply chain
Therapeutic areas
Epileptic seizure
Acute adrenal crisis
Anaphylactic shock
Severe asthma crisis
Migraines and cluster headaches
Opioid overdose
Rheumatoid arthritis
Main navigation 2 EN
Finances
Profile
Analyst coverage
Financial releases
News
Our news
Press releases
Careers
Working at Crossject
Contact
Search
Search
Enter the terms you wish to search for.
Home
Finances
2021 annual results - First Marketing Authorization (MA) applications expected to be filed in 2023
2021 annual results - First Marketing Authorization (MA) applications expected to be filed in 2023
Image
Date de parution
2022/04/05
PDF du document
Crossject_Résultats 2021 et point d'activité_VDEF V EN.pdf
762.68 KB
